期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 30, 期 6, 页码 1195-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2016.07.004
关键词
Relapsed/refractory DLBCL; Autologous transplant; Salvage chemotherapy; Prognosis; CD20 antibody
Second-line therapy options for patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to, or relapses after, current rituximab-containing primary therapy continue to evolve. For younger patients, salvage therapy followed by intensive therapy and autologous stem cell transplant (ASCT) remains the treatment of choice for those with chemotherapy-sensitive disease. Combination therapy may be used for those who are not candidates for ASCT. In contrast, patients with DLBCL refractory to 2 lines of therapy have a very poor prognosis and generally short survival, and should be carefully considered for participation in clinical trials of novel approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据